Plant ID: NPO2852
Plant Latin Name: Cirsium canum
Taxonomy Genus: Cirsium
Taxonomy Family: Asteraceae
NCBI TaxonomyDB:
196709
Plant-of-the-World-Online:
n.a.
MAPK1; | |
CA13; CA7; CA12; CA9; | |
GFER; HSD17B10; ALDH1A1; | |
CASP7; CASP1; | |
NPC1; RAB9A; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 2 | CYP2A13 | Cytochrome P450 2A13 | Q16696 | CHEMBL3542436 |
Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 7.907E-12 | 8.608E-08 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.047E-10 | 5.701E-07 | CYP2A13, CYP2A6, CYP2C19, CYP2D6, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.600E-10 | 9.436E-07 | CYP1A2, CYP2A6, CYP2C19, CYP3A4 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.570E-10 | 1.422E-06 | CYP1A2, CYP2A13, CYP2C19, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 7.157E-10 | 1.948E-06 | CA12, CA13, CA7, CA9 |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.309E-09 | 2.850E-06 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.127E-09 | 5.675E-06 | CYP1A2, CYP2A13, CYP2A6, CYP2C19 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.622E-09 | 6.868E-06 | CYP1A2, CYP2A13, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 5.027E-09 | 6.868E-06 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 2.373E-08 | 2.272E-05 | CYP2A13, CYP2A6, CYP2D6 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.051E-08 | 2.658E-05 | CA12, CA13, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 5.282E-08 | 3.834E-05 | CYP1A2, CYP2A13, CYP2C19, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 6.716E-08 | 4.718E-05 | CYP1A2, CYP2A6, CYP2C19, CYP2D6, CYP3A4, NPC1 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.999E-08 | 4.763E-05 | CA12, CA13, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.487E-07 | 9.251E-05 | CYP1A2, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 4.583E-07 | 2.495E-04 | CYP2A13, CYP2A6, CYP2C19 |
MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 8.202E-07 | 4.252E-04 | CYP2A13, CYP2A6 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 2.459E-06 | 1.245E-03 | CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.916E-06 | 2.327E-03 | CYP1A2, CYP3A4 |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.097E-05 | 4.778E-03 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2D6, CYP3A4, RAB9A |
BP | GO:0050896; response to stimulus | GO:0046686; response to cadmium ion | 1.826E-05 | 7.364E-03 | CYP1A2, MAPK1, NPC1 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 3.489E-09 | 1.644E-07 | CYP2A6, CYP2D6, CYP1A2, CYP3A4, CYP2C19 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 4.654E-09 | 1.644E-07 | CYP2A6, CYP2A13, CYP2D6, CYP1A2, CYP3A4 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.085E-09 | 1.150E-07 | CA12, CA7, CA9, CA13 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 8.412E-09 | 2.229E-07 | CYP2A6, CYP2A13, CYP1A2, CYP3A4, CYP2C19 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 3.004E-07 | 6.369E-06 | CYP2A6, CYP1A2, ALDH1A1, CYP3A4 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 2.204E-06 | 3.894E-05 | CYP1A2, CYP3A4, CYP2C19 |
09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 3.969E-05 | 5.259E-04 | CASP7, CASP1, MAPK1 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.312E-04 | 1.545E-03 | CYP2D6, MAPK1, CYP2C19 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 5.430E-04 | 5.233E-03 | CYP2A6, CYP1A2, ALDH1A1, CYP2C19, CYP3A4, HSD17B10 |
09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05010 | Alzheimer's disease | 4.330E-04 | 4.590E-03 | CASP7, MAPK1, HSD17B10 |
09160 Human Diseases | 09167 Infectious diseases | hsa05134 | Legionellosis | 1.104E-03 | 8.674E-03 | CASP7, CASP1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00983 | Drug metabolism - other enzymes | 7.735E-04 | 6.832E-03 | CYP2A6, CYP3A4 |
09150 Organismal Systems | 09151 Immune system | hsa04621 | NOD-like receptor signaling pathway | 1.186E-03 | 8.674E-03 | CASP1, MAPK1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.227E-03 | 8.674E-03 | CYP1A2, CYP3A4 |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 7.638E-06 | 1.157E-04 | CYP2A6, CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; |
C00-D49: Neoplasms | Breast cancer | C50 | CA9; |
C00-D49: Neoplasms | Cancer | C00-C96 | CA9; |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; |